Vir Biotechnology

Vir Biotechnology and Bill & Melinda Gates Foundation to develop vaccinal antibody tech for tackling HIV and malaria

17-Jan-2022 By Rachel Arthur

Vir Biotechnology and the Bill & Melinda Gates Foundation have partnered up to develop broadly neutralizing antibodies designed to provide a ‘vaccinal effect’ for the treatment of HIV and prevention of malaria.

GSK and Vir Biotechnology add new influenza therapeutics to coronavirus collaboration

18-Feb-2021 By Rachel Arthur

In 2020, GSK and Vir Biotechnology partnered to research and develop therapies for coronaviruses. This agreement has now been extended to include new therapies for influenza and other respiratory viruses, with GSK investing $345m in the extended partnership.

Vir continues to build production for COVID-19 antibody

14-Apr-2020 By Ben Hargreaves

In its latest manufacturing partnership, Vir announces that it will work with Samsung Biologics for large-scale production.

GSK and Vir launch collaboration on coronavirus

07-Apr-2020 By Ben Hargreaves

In two separate announcements, GSK unveils that it will partner with Vir to combat COVID-19, as well as investing in the biotech.

George Scangos to lead BIO’s efforts against coronavirus

02-Mar-2020 By Ben Hargreaves

The ex-Biogen CEO will coordinate the biotech organization’s response to the virus.